Mostrar el registro sencillo del ítem
A radiobiological study of the schemes with a low number of fractions in high-dose-rate brachytherapy as monotherapy for prostate cancer
dc.contributor.author | Guirado Llorente, Damián | |
dc.contributor.author | Ruiz-Arrebola, Samuel | |
dc.contributor.author | Tornero-López, Ana M. | |
dc.contributor.author | de la Vega, Jose M. | |
dc.contributor.author | Prada, Pedro J. | |
dc.contributor.author | Lallena Rojo, Antonio Miguel | |
dc.date.accessioned | 2020-06-03T08:11:14Z | |
dc.date.available | 2020-06-03T08:11:14Z | |
dc.date.issued | 2020-04-18 | |
dc.identifier.citation | Damián Guirado, Samuel Ruiz-Arrebola, Ana M. Tornero-López, et al. A radiobiological study of the schemes with a low number of fractions in high-dose-rate brachytherapy as monotherapy for prostate cancer. J Contemp Brachytherapy. 2020;12(2):193‐200. [doi:10.5114/jcb.2020.94492] | es_ES |
dc.identifier.uri | http://hdl.handle.net/10481/62341 | |
dc.description.abstract | Purpose Schemes with high doses per fraction and small number of fractions are commonly used in high-dose-rate brachytherapy (HDR-BT) for prostate cancer. Our aim was to analyze the differences between published clinical results and the predictions of radiobiological models for absorbed dose required in a single fraction monotherapy HDR-BT. Material and methods Published HDR-BT clinical results for low- and intermediate-risk patients with prostate cancer were revised. For 13 clinical studies with 16 fractionation schedules between 1 and 9 fractions, a dose-response relation in terms of the biochemical control probability (BC) was established using Monte Carlo-based statistical methods. Results We obtained a value of α/β = 22.8 Gy (15.1-60.2 Gy) (95% CI) much larger than the values in the range 1.5-3.0 Gy that are usually considered to compare the results of different fractionation schemes in prostate cancer radiotherapy using doses per fraction below 6 Gy. The doses in a single fraction producing BC = 90% and 95% were 22.3 Gy (21.5-24.2 Gy) and 24.3 Gy (23.0-27.9 Gy), respectively. Conclusions The α/β obtained in our analysis of 22.8 Gy for a range of dose per fraction between 6 and 20.5 Gy was much greater than the one currently estimated for prostate cancer using low doses per fraction. This high value of α/β explains reasonably well the data available in the region of high doses per fraction considered. | es_ES |
dc.description.sponsorship | Spanish Ministerio de Ciencia y Competitividad FPA2015-67694-P | es_ES |
dc.description.sponsorship | European Union (EU) | es_ES |
dc.description.sponsorship | Junta de Andalucía FQM0387 | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Termedia Publishing | es_ES |
dc.rights | Atribución-NoComercial-CompartirIgual 3.0 España | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/3.0/es/ | * |
dc.subject | HDR brachytherapy | es_ES |
dc.subject | Prostate cancer | es_ES |
dc.subject | Monotherapy | es_ES |
dc.title | A radiobiological study of the schemes with a low number of fractions in high-dose-rate brachytherapy as monotherapy for prostate cancer | es_ES |
dc.type | journal article | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.identifier.doi | 10.5114/jcb.2020.94492 |